

**Date: 10 November 2025**

**To**

The Secretary

**BSE Limited**

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai - 400 001

**Scrip Code: 544293**

The Secretary

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block

Bandra -Kurla Complex, Bandra (East)

Mumbai- 400 051

**Scrip Symbol : SURAKSHA**

Dear Sir / Ma'am,

**Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

**Sub: Press release in respect of unaudited (standalone and consolidated) financial results of the Company for quarter and six months ended 30 September 2025**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the unaudited (standalone and consolidated) financial results of the Company for quarter and six months ended 30 September 2025.

Further, details as required to be disclosed as per BSE's Circular No. 20230714-34 dated 14 July 2023, and NSE's Circular No. NSE/CML/2023/57 dated 14 July 2023, are as under:

Date of occurrence of Event/Information: 10 November 2025

Time of occurrence of Event/Information: 4.15 pm (IST)

This may please be informed to all the concerned.

For **Suraksha Diagnostic Limited**

---

**Mamta Jain**

Company Secretary & Compliance Officer

**Encl:** As above

**Suraksha Diagnostic Limited**

**CIN:** L85110WB2005PLC102265

**Reg Office:** 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town  
Kolkata-700 156, West Bengal, India

**E-mail:** investors@surakshanet.com | **Website:** www.surakshanet.com

**Phone:**(033) 6605 9750





# Suraksha Diagnostics Ltd announces H1 FY26 results with a 17.8% YoY revenue growth

*Total Income grew by 16.9% year-on-year in Q2 FY26*

*Q2 FY26 EBITDA grew by 1.9% year-on-year*

**Kolkata, 10<sup>th</sup> November 2025:** Suraksha Diagnostic Limited, the largest integrated diagnostic chain in Eastern India, announced its unaudited financial results for the quarter and half year ended 30<sup>th</sup> September 2025.

## H1 FY26 Financial Performance Snapshot (Y-o-Y)

Total Income	EBITDA	Profit After Tax	EPS
₹ 1,530.72 million	₹ 496.22 million	₹ 180.03 million	₹ 3.53
 +17.8%	 +7.3%	 +1.0%	 ₹ 0.10

## Key Financial Highlights

Particulars	Q2 FY26	Q2 FY25	Y-o-Y	H1 FY26	H1 FY25	Y-o-Y
Total Income (₹ million)	795.80	680.67	16.9%	1,530.72	1,299.15	17.8%
EBTIDA (₹ million)	249.66	245.07	1.9%	496.22	462.28	7.3%
EBTIDA Margin (%)	31.7%	36.7%		32.8%	36.3%	
PAT (₹ million)	88.28	101.56	-13.1%	180.03	178.22	1.0%
PAT Margin (%)	11.2%	15.2%		11.9%	14.0%	

## Key Operational Highlights

Particulars	Q2 FY26	Q2 FY25	Y-o-Y	H1 FY26	H1 FY25	Y-o-Y
Total tests (# million)	2.20	1.71	29.2%	4.13	3.29	25.6%
Total Patients (# million)	0.38	0.32	18.2%	0.71	0.61	17.5%
Tests per patient (#)	5.83	5.34	9.2%	5.78	5.41	6.8%
Average Revenue per test (₹)	357	391	-8.7%	367	388	-5.5%
Average Revenue per patient (₹)	2,083	2,088	-0.2%	2,120	2,099	1.0%

**Commenting on the results Mrs. Ritu Mittal, Joint Managing Director & CEO said, -**

*“Suraksha reported another quarter of strong top-line growth, driven primarily by test volumes. The QoQ and YoY total revenue growth was 8.3% and 16.9%, respectively.*

*I am happy to announce that we have added 11 centres in H1 of FY26. We are working on 3 hub centres and 6 spoke centres, which will be operational in the second half of FY26, which will take the total count to 20 for the year.*

*In Q1 FY26, we launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and molecular testing services. The lab is now fully operational and we expect to leverage the same to drive future growth.*

*As the new centres mature, their margin contributions will increase, moving overall performance closer to industry benchmarks and supporting improved profitability across our network.*

*We remain committed to creating value for our shareholders, driven by innovation, operational excellence and sustainable growth.”*

**About Suraksha Diagnostic Limited:**

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with a presence in the states of West Bengal, Bihar, Assam and Meghalaya.

The company’s central reference laboratory is accredited by the College of American Pathologists, while the 4 laboratories hold National Accreditation Board for testing and calibration Laboratories (NABL) accreditation, and the 3 advanced diagnostic centres are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Company: Suraksha Diagnostic Limited	Investor Relations: Orient Capital
Email: <a href="mailto:investors@surakshanet.com">investors@surakshanet.com</a>	Name: Mr. Ashish Tendulkar Email: ashish.tendulkar@in.mpms.mufg.com
CIN: L85110WB2005PLC102265	Name: Pooja Swami Email: pooja.swami@in.mpms.mufg.com
Website: <a href="https://www.surakshanet.com/">https://www.surakshanet.com/</a>	Meeting Request Link – <a href="#">Click Here</a>

**Safe Harbor**

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.